VEGFA and nasopharyngeal carcinoma: To test our hypothesis that lenvatinib overcomes AAD resistance in NPC, we treated NPC-bearing mice with anti-VEGF or lenvatinib at clinically relevant doses, both of which inhibited AAD-sensitive CRC for approximately 50% (Fig. 1 and Supplementary Fig. S5A).